docetaxel anhydrous has been researched along with bromocriptine in 2 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (bromocriptine) | Trials (bromocriptine) | Recent Studies (post-2010) (bromocriptine) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 7,121 | 727 | 499 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | bromocriptine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.532 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 2.4 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 2.4996 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.015 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0016 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 2.281 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.035 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.52 | |
| D | Rattus norvegicus (Norway rat) | 0.0279 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0279 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0056 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.514 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 2.889 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.514 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.514 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.03 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0279 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.036 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.532 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.0056 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0279 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.0006 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.0083 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.022 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0279 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, Y; Du, Y; Fu, H; Kavuri, S; Kucuk, O; Li, X; Mamouni, K; Wu, D; Yang, Y | 1 |
1 review(s) available for docetaxel anhydrous and bromocriptine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for docetaxel anhydrous and bromocriptine
| Article | Year |
|---|---|
Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bromocriptine; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Docetaxel; Dopamine Agonists; Drug Repositioning; Drug Synergism; Humans; Male; Mice, Nude; Prostatic Neoplasms; Receptors, Dopamine D2; Xenograft Model Antitumor Assays | 2018 |